LONDON, Oct. 5, 2015 /PRNewswire/ -- Off–label
prescribing of medicines is prevalent worldwide because it gives
freedom to physicians to apply new therapeutic options based on the
latest evidence. Although physicians may lawfully prescribe
approved Drugs for any use consistent with available scientific
data and proper medical practice, but unfortunately, this is done
without adequate scientific data. Often, when the best available
therapeutic option fails, patients demand new approach or new
treatment which ultimately leads to off–label uses.
Off–label use is very common in United
States. United States Off–label Drugs demand has grown at a
fast pace in the past decade and likely to grow in the forecasting
period. It is likely that United
States off–label market will cross the figure of 60 Billion
by the year 2020. Central Nervous System (CNS) and Cancer off–label
Drugs controls the largest market share of the total US off–label
Drugs market. Anti–Infectives Off–Label Drugs Market and
Anti–Ashmatics Off–Label Drugs together are expected to control
close to 35% market share by 2020.
Renub Research study titled "United States Off–Label Drugs Market
& Forecast" report provides a comprehensive analysis of the
emerging Off–Label Drugs market. The report also entails commonly
prescribed Off–Label Drugs, Perspective of Physicians, Patients,
Pharmaceutical Companies and Regulatory Authorities, Off–label
Promotion Settlements under the False Claims Act. The report also
studies Drivers and Challenges of United States Off–Label Drugs
market. This 67 page report with 16 Figures and 1 Table studies 6
Off–Label Drugs Segment.
The 6 Off–Label Drugs Segment Covered in the Report are as
Follows:
1. Cancer Off–Label Drugs
2. Central Nervous System (CNS) Off–Label Drugs
3. Anti–Ashmatics Off–Label Drugs
4. Anti–Allergies Off–Label Drugs
5. Anti–Hypertensives Off–Label Drugs
6. Anti–Infectives Off–Label Drugs
Data Sources
This report is built using data and information sourced from
proprietary databases, primary and secondary research and in–house
analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephonic interviews
with industry experts.
Secondary sources information and data has been collected from
various printable and non–printable sources like search engines,
News websites, Government Websites, Trade Journals, White papers,
Government Agencies, Magazines, Newspapers, Trade associations,
Books, Industry Portals, Industry Associations and access to more
than 500 paid databases.
Download the full report:
https://www.reportbuyer.com/product/2867917/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that
provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/united-states-offlabel-drugs-market--forecast-300154545.html
SOURCE ReportBuyer